Stephanie Niño de Rivera

Stephanie Niño de Rivera

Auto-generated profile, based on publicly available information

Stephanie Niño de Rivera

Weill Cornell Medicine, New York, NY (S.N.d.R., B.R.).

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SRStephanie Niño de Rivera
Stephanie Niño de Rivera
RCRuth Masterson Creber
Ruth Masterson Creber
YZYihong Zhao
Yihong Zhao
SESarah Eslami
Sarah Eslami
SMSabrina Mangal
Sabrina Mangal
MTMeghan Reading Turchioe
Meghan Reading Turchioe
The National Institutes of Health (NIH) is the largest public research funder in the world. In an effort to make publicly funded data more accessible, the NIH established a new Data Management and Sharing (DMS) Policy effective January 2023. Though the new policy was available for public comment, the patient perspective and the potential unintended consequences of the policy on patients’ willingness to participate in research have been underexplored. This study aimed to determine: (1) participant preferences about the types of data they are willing to share with external entities, and (2) participant perspectives regarding the updated 2023 NIH DMS policy. A cross-sectional, nationally representative online survey was conducted among 610 English-speaking US adults in March 2023 using Prolific. Overall, 50% of the sample identified as women, 13% as Black or African American, and 7% as Hispanic or Latino, with a mean age of 46 years. The majority of respondents (65%) agreed with the NIH policy, but racial differences were noted with a higher percentage (28%) of Black participants indicating a decrease in willingness to participate in research studies with the updated policy in place. Participants were more willing to share research data with healthcare providers, yet their preferences for data sharing varied depending on the type of data to be shared and the recipients. Participants were less willing to share sexual health and fertility data with health technology companies (41%) and public repositories (37%) compared to their healthcare providers (75%). The findings highlight the importance of adopting a transparent approach to data sharing that balances protecting patient autonomy with more open data sharing.

19 July 2024 in JMIR Nursing
Verified
Journal Article
Open access
BTBrittany Taylor
Brittany Taylor
MHMollie Hobensack
Mollie Hobensack
SRStephanie Niño de Rivera
Stephanie Niño de Rivera
YZYihong Zhao
Yihong Zhao
RCRuth Marie Masterson Creber
Ruth Marie Masterson Creber
KCKenrick Cato
Kenrick Cato
Background: Depression is one of the most common mental disorders that affects >300 million people worldwide. There is a shortage of providers trained in the provision of mental health care, and the nursing workforce is essential in filling this gap. The diagnosis of depression relies heavily on self-reported symptoms and clinical interviews, which are subject to implicit biases. The omics methods, including genomics, transcriptomics, epigenomics, and microbiomics, are novel methods for identifying the biological underpinnings of depression. Machine learning is used to analyze genomic data that includes large, heterogeneous, and multidimensional data sets. Objective: This scoping review aims to review the existing literature on machine learning methods for omics data analysis to identify individuals with depression, with the goal of providing insight into alternative objective and driven insights into the diagnostic process for depression. Methods: This scoping review was reported following the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) guidelines. Searches were conducted in 3 databases to identify relevant publications. A total of 3 independent researchers performed screening, and discrepancies were resolved by consensus. Critical appraisal was performed using the Joanna Briggs Institute Critical Appraisal Checklist for Analytical Cross-Sectional Studies. Results: The screening process identified 15 relevant papers. The omics methods included genomics, transcriptomics, epigenomics, multiomics, and microbiomics, and machine learning methods included random forest, support vector machine, k-nearest neighbor, and artificial neural network. Conclusions: The findings of this scoping review indicate that the omics methods had similar performance in identifying omics variants associated with depression. All machine learning methods performed well based on their performance metrics. When variants in omics data are associated with an increased risk of depression, the important next step is for clinicians, especially nurses, to assess individuals for symptoms of depression and provide a diagnosis and any necessary treatment.

6 June 2024 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
RCRuth Marie Masterson Creber
Ruth Marie Masterson Creber
ADArnaldo Dimagli
Arnaldo Dimagli
SRStephanie Niño de Rivera
Stephanie Niño de Rivera
DRDavid Russell
David Russell
SGStephen Gerry
Stephen Gerry
MGMario Gaudino
Mario Gaudino
OBJECTIVES: This article identifies minimal clinically important differences (MCIDs) in quality of life (QoL) measures among patients who had coronary artery bypass grafting (CABG) and were enrolled in the arterial revascularization trial (ART). METHODS AND RESULTS: The European Quality of Life-5 Dimensions (EQ-5D) and the Short Form Health Survey 36-Item (SF-36) physical component (PC) and mental component (MC) scores were recorded at baseline, 5 years and 10 years in ART. The MCIDs were calculated as changes in QoL scores anchored to 1-class improvement in the New York Heart Association functional class and Canadian Cardiovascular Society scale at 5 years. Cox proportional hazard models were used to evaluate associations between MCIDs and mortality. Patient cohorts were examined for the SF-36 PC (N = 2671), SF-36 MC (N = 2815) and EQ-5D (N = 2943) measures, respectively. All QoL scores significantly improved after CABG compared to baseline. When anchored to the New York Heart Association, the MCID at 5 years was 17 (95% confidence interval: 17–20) for SF-36 PC, 14 (14–17) for the SF-36 MC and 0.12 (0.12–0.15) for EQ-5D. Using the Canadian Cardiovascular Society scale as an anchor, the MCID at 5 years was 15 (15–17) for the SF-36 PC, 12 (13–15) for the SF-36 MC and 0.12 (0.11–0.14) for the EQ-5D. The MCIDs for SF-36 PC and EQ-5D at 5 years were associated with a lower risk of mortality at the 10-year follow-up point after surgery. CONCLUSIONS: MCIDs for CABG patients have been identified. These thresholds may have direct clinical applications in monitoring patients during follow-up and in designing new trials that include QoL as a primary study outcome. Clinical trial registration number: ISRCTN46552265.

26 April 2024 in Journal of Medical Internet Research
Verified
Journal Article
Open access
NBNatalie Benda
Natalie Benda
SWSydney Woode
Sydney Woode
SRStephanie Niño de Rivera
Stephanie Niño de Rivera
RKRobin B Kalish
Robin B Kalish
LRLaura E Riley
Laura E Riley
JAJessica S Ancker
Jessica S Ancker
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Pregnancy-related death is on the rise in the United States, and there are significant disparities in outcomes for Black women. Most solutions addressing climbing pregnancy-related death rates are hospital based and rely on women recognizing symptoms and seeking care from a health system, which is an area where many black women have reported experiencing bias. Objective: To determine design needs an mHealth patient reported outcome and decision support system to assist Black women in determining when to seek medical care for concerning postpartum symptoms. Methods: We conducted semi-structured interviews with 15 obstetric health professionals, 10 mental health professionals, and 11 postpartum Black women. Our questions pertained to current practices for symptom monitoring, barriers, facilitators, design, and informational needs for and mHealth system to support monitoring for severe symptoms. Results: Our findings revealed the importance of including both somatic and psychological symptoms in the system; considering how external drivers (e.g., sociocultural, financial, structural) may affect how women process, make decisions about, and act upon their symptoms; and that system design should allow different interaction pathways and personalization. Conclusions: Future solutions for postpartum symptom monitoring should include both somatic and psychological symptoms and allow for varied, safe different interactions to suit individual needs. Clinical Trial: Not applicable

22 November 2023 in JMIR Preprints
Verified
Preprint
Open access
BTBrittany Taylor
Brittany Taylor
MHMollie Hobensack
Mollie Hobensack
SRStephanie Niño de Rivera
Stephanie Niño de Rivera
YZYihong Zhao
Yihong Zhao
RCRuth Marie Masterson Creber
Ruth Marie Masterson Creber
KCKenrick Cato
Kenrick Cato
BACKGROUND Depression is one of the most common mental disorders that affects >300 million people worldwide. There is a shortage of providers trained in the provision of mental health care, and the nursing workforce is essential in filling this gap. The diagnosis of depression relies heavily on self-reported symptoms and clinical interviews, which are subject to implicit biases. The omics methods, including genomics, transcriptomics, epigenomics, and microbiomics, are novel methods for identifying the biological underpinnings of depression. Machine learning is used to analyze genomic data that includes large, heterogeneous, and multidimensional data sets. OBJECTIVE This scoping review aims to review the existing literature on machine learning methods for omics data analysis to identify individuals with depression, with the goal of providing insight into alternative objective and driven insights into the diagnostic process for depression. METHODS This scoping review was reported following the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) guidelines. Searches were conducted in 3 databases to identify relevant publications. A total of 3 independent researchers performed screening, and discrepancies were resolved by consensus. Critical appraisal was performed using the Joanna Briggs Institute Critical Appraisal Checklist for Analytical Cross-Sectional Studies. RESULTS The screening process identified 15 relevant papers. The omics methods included genomics, transcriptomics, epigenomics, multiomics, and microbiomics, and machine learning methods included random forest, support vector machine, k-nearest neighbor, and artificial neural network. CONCLUSIONS The findings of this scoping review indicate that the omics methods had similar performance in identifying omics variants associated with depression. All machine learning methods performed well based on their performance metrics. When variants in omics data are associated with an increased risk of depression, the important next step is for clinicians, especially nurses, to assess individuals for symptoms of depression and provide a diagnosis and any necessary treatment.

12 June 2026 in Circulation: Population Health and Outcomes
Verified
Journal Article
Closed access
SRStephanie Niño de Rivera
Stephanie Niño de Rivera
NSNiurka Suero-Tejeda
Niurka Suero-Tejeda
RMRhonda Monroe
Rhonda Monroe
MTMatthew Tang
Matthew Tang
SESarah Eslami
Sarah Eslami
RCRuth Marie Masterson Creber
Ruth Marie Masterson Creber
BACKGROUND: Women, Black, and Hispanic patients bear a disproportionate burden of cardiovascular disease yet remain underrepresented in clinical trials. Understanding patient perspectives is essential to developing inclusive recruitment strategies in cardiovascular research. METHODS: The RECHARGE trial (Revascularization Choices Among Underrepresented Groups Evaluation) is an ongoing comparative effectiveness study comparing percutaneous coronary intervention and coronary artery bypass grafting among women, Black, and Hispanic patients. To inform recruitment strategies, we conducted a qualitative study using in-person and virtual focus groups and semistructured interviews. Participants were US adults who identified as Black or Hispanic and had a history of percutaneous coronary intervention, coronary artery bypass grafting, or advanced cardiovascular disease. Interviews were guided by the Social-Ecological Model and analyzed using directed content analysis with a constant comparative approach. RESULTS: The sample included 42 participants (35 women, 7 men); 29 identified as Hispanic and 13 as Black. Barriers and facilitators to trial participation spanned multiple levels of the Social-Ecological Model. At the individual and interpersonal levels, barriers included complex study materials, excessive medical jargon, and mistrust of randomization, with concerns about being assigned a less effective treatment. At community and societal levels, participants cited limited recruitment outreach, lack of culturally and linguistically appropriate materials, and mistrust stemming from historical research injustices. Facilitators included trust in healthcare providers, reassurance regarding treatment appropriateness, and involvement of family or support systems. At the community and societal levels, accessible, visual, and multilingual materials were highlighted to support understanding. Participants emphasized the value of plain language, visual, and multilingual materials, adequate time for shared decision-making, and transparent communication about study goals. CONCLUSIONS: Increasing representation of underrepresented populations in cardiovascular trials requires transparent, accessible communication and trust-centered recruitment strategies. Leveraging trusted healthcare providers and community-based outreach is critical to advancing equity in cardiovascular research. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT06399705 and NCT06399692.